Vindesine
drugOn this page
Also known as COMPOUND 112531COMPOUND-112531Vindesinadesacetylvinblastine[3H]-VindesineVindesineÊVindesineÂ
Summary
Vindesine (CHEMBL238071) is an approved small molecule (ATC L01CA03); indicated across 16 conditions including neoplasm and acute lymphoblastic leukemia.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: L01CA03
- Indications: 16 conditions
- Clinical trials: 44
- Chemistry: 753.9 Da · C43H55N5O7
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL238071 |
| Name | Vindesine |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | no |
| PubChem CID | 11643449 |
| ATC | L01CA03 |
| Molecular formula | C43H55N5O7 |
| Molecular weight | 753.9 |
| InChIKey | HHJUWIANJFBDHT-ZVTSDNJWSA-N |
SMILES: CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)N)O)O)CC)OC)C(=O)OC)O
IUPAC name: methyl (13S,15R,17S)-13-[(1R,9R,10S,11R,12R,19R)-10-carbamoyl-12-ethyl-10,11-dihydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-17-hydroxy-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraene-13-carboxylate
Also known as: COMPOUND 112531, COMPOUND-112531, Vindesina, Vindesine, vindesine, desacetylvinblastine, VINDESINE, [3H]-Vindesine, VindesineÊ, VindesineÂ
Parent form; salt/anhydrous children: CHEMBL3989543
Patent coverage: 193 distinct patent families (384 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 380 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Motilin receptor, Prostaglandin G/H synthase 2, Voltage-gated inwardly rectifying potassium channel KCNH2, Prostaglandin G/H synthase 1, Growth hormone secretagogue receptor type 1.
Bioactivity
ChEMBL activities: 2 potent at pChembl ≥ 5 of 5 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| MLNR | 5.32 | AC50 | 4800 | nM | CHEMBL_ACT_25189277 |
| GHSR | 5.19 | AC50 | 6500 | nM | CHEMBL_ACT_25172845 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
16 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| neoplasm | 4 | MONDO:0005070 | EFO:0000616 |
| acute lymphoblastic leukemia | 3 | MONDO:0004967 | EFO:0000220 |
| diffuse large B-cell lymphoma | 3 | MONDO:0018905 | EFO:0000403 |
| leukemia | 3 | MONDO:0005059 | EFO:0000565 |
| lymphoma | 3 | MONDO:0005062 | EFO:0000574 |
| neuroblastoma | 3 | MONDO:0005072 | EFO:0000621 |
| lung neoplasm | 3 | MONDO:0021117 | MONDO:0008903 |
| peripheral T-cell lymphoma, not otherwise specified | 2 | MONDO:0004964 | EFO:0000211 |
| small cell lung carcinoma | 2 | MONDO:0008433 | EFO:0000702 |
| neoplasm of mature B-cells | 2 | MONDO:0004949 | EFO:0000096 |
| non-Hodgkin lymphoma | 1 | MONDO:0018908 | EFO:0005952 |
5 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 44.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 21 |
| PHASE2 | 9 |
| PHASE4 | 6 |
| Not specified | 5 |
| PHASE2/PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00198991 | PHASE4 | COMPLETED | German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003) |
| NCT00199004 | PHASE4 | COMPLETED | Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab |
| NCT00199017 | PHASE4 | COMPLETED | German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults |
| NCT00199056 | PHASE4 | COMPLETED | German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99) |
| NCT00199082 | PHASE4 | COMPLETED | Newly Diagnosed Mature B-ALL, Burkitt’s Lymphoma and Other High-grade Lymphoma in Adults |
| NCT00226473 | PHASE4 | UNKNOWN | Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma |
| NCT02845882 | PHASE3 | ACTIVE_NOT_RECRUITING | LBL-2016 for Children or Adolescents in China |
| NCT03643276 | PHASE3 | RECRUITING | Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 |
| NCT04043494 | PHASE3 | RECRUITING | International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma |
| NCT04221035 | PHASE3 | RECRUITING | High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) |
| NCT05681260 | PHASE3 | RECRUITING | Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL) |
| NCT06361329 | PHASE3 | RECRUITING | Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL |
| NCT00002802 | PHASE3 | COMPLETED | Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma |
| NCT00002823 | PHASE3 | COMPLETED | Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer |
| NCT00003209 | PHASE3 | COMPLETED | Radiation Therapy With or Without Chemotherapy After Surgery in Treating Patients With Stage IB or Stage IIA Cervical Cancer |
| NCT00003240 | PHASE3 | UNKNOWN | Standard Therapy Given With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer |
| NCT00003728 | PHASE3 | UNKNOWN | Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin’s Lymphoma |
| NCT00135499 | PHASE3 | TERMINATED | R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma |
| NCT00410631 | PHASE3 | UNKNOWN | Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma |
| NCT00430118 | PHASE3 | COMPLETED | Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia |
| NCT00613457 | PHASE3 | COMPLETED | Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia |
| NCT00764907 | PHASE3 | UNKNOWN | Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia |
| NCT00920153 | PHASE3 | TERMINATED | Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma |
| NCT01117441 | PHASE3 | COMPLETED | International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia |
| NCT02767674 | PHASE3 | UNKNOWN | Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma |
| NCT02871869 | PHASE2/PHASE3 | UNKNOWN | Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma |
| NCT02881086 | PHASE3 | COMPLETED | Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment |
| NCT03018626 | PHASE3 | UNKNOWN | R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCL |
| NCT06713057 | PHASE2 | NOT_YET_RECRUITING | Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer |
| NCT07159620 | PHASE2 | RECRUITING | Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients |
| NCT00002531 | PHASE2 | UNKNOWN | Combination Chemotherapy in Treating Adults With Acute Lymphocytic Leukemia |
| NCT00002532 | PHASE2 | UNKNOWN | Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia |
| NCT00017225 | PHASE2 | COMPLETED | Chemotherapy and Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma |
| NCT00136565 | PHASE2 | COMPLETED | Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma |
| NCT00759824 | PHASE2 | COMPLETED | A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide |
| NCT02987244 | PHASE1/PHASE2 | UNKNOWN | Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma |
| NCT04899570 | PHASE2 | UNKNOWN | Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma |
| NCT05049473 | PHASE2 | UNKNOWN | Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14. |
| NCT00002887 | PHASE1 | UNKNOWN | Hydroxyurea Plus Combination Chemotherapy in Patients With Non-small Cell Lung Cancer |
| NCT00317408 | Not specified | UNKNOWN | Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).